Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 51 to 75 of 741

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884

Results per page

  1. 10
  2. 25
  3. 50
  4. All